论文部分内容阅读
目的 :探讨 CD4 4 v6、v9和 P5 3蛋白联合表达在人喉癌发生、发展及预后中的作用。 方法 :采用免疫组织化学 En Vi-sion法检测 2 2 3例喉不同病变组织标本 (喉癌 14 3例 ,喉癌前病变 32例 ,声带息肉 39例和癌周正常喉组织 9例 )中 CD4 4 v6、v9和 P5 3蛋白的表达。 结果 :(1) CD4 4 v6、v9和 P5 3在人喉癌组织中表达阳性率分别为 72 .7% (10 4 / 14 3)、5 6 .6 % (81/ 14 3)和 5 2 .4 % (75 / 14 3) ;喉癌前病变组织中为 37.5 % (12 / 32 )、31.3(10 / 32 ) %和 2 1.9% (7/ 32 ) ;声带息肉中为 17.9% (7/ 39)、12 .8% (5 / 39)和 10 .3% (4 / 39) ;癌周正常喉组织中均为 0 (0 / 9) ;3种蛋白在喉癌组织中阳性表达率均显著高于癌前病变及声带息肉组织 (P<0 .0 1)。 (2 ) CD4 4 v6、v9和 P5 3在人喉癌组织中联合表达阳性率为 4 1.3% (5 9/ 14 3) ,显著高于其他喉不同病变组织中联合表达阳性率 (8.8% ,7/ 80 ,P<0 .0 1)。 (3) CD4 4 v6、v9和 P5 3在 - 期喉癌组织中表达阳性率分别为 5 6 .5 %(35 / 6 2 )、4 0 .3% (2 5 / 6 2 )和 38.7% (2 4 / 6 2 ) ,均显著低于 - 期喉癌组织 [分别为 85 .2 % (6 9/ 81)、6 9.1% (5 6 / 81)和 6 2 .9%(5 1/ 81) ,P<0 .0 1]。 (4 ) CD4 4 v6、v9和 P5 3在伴颈淋巴结转?
Objective: To investigate the role of CD4 4 v6, v9 and P53 protein in the occurrence, development and prognosis of human laryngeal carcinoma. Methods: Immunohistochemistry En Vi-sion method was used to detect CD4 (superscript +) CD25 in different tissues of larynx (147 in laryngeal cancer, 32 in precancerous lesions, 39 in vocal cord polyps and 9 in normal laryngeal tissues) 4 v6, v9 and P53 protein expression. Results: (1) The positive rates of CD4 4 v6, v9 and P53 in human laryngeal squamous cell carcinoma were 72.7% (104/14 3), 56.6% (81/14 3) and 52 (7/32) in the premalignant lesions of the laryngeal carcinoma were 17.5% (12/32), 31.3 (10/32)% and 2 1.9% (7/32) / 39), 12.8% (5/39) and 10.3% (4/39) respectively. The normal laryngeal tissues were 0 (0/9) Were significantly higher than the precancerous lesions and vocal cord polyps (P <0.01). (2) The positive rate of co-expression of CD4 4 v6, v9 and P5 3 in human laryngeal squamous cell carcinoma was 41.3% (59/14 3), which was significantly higher than that in other laryngeal tissues (8.8% 7/80, P <0. 01). (3) The positive expression rates of CD4 4 v6, v9 and P53 in - stage laryngeal squamous cell carcinoma were 56.5% (35/62), 40.3% (25/62) and 38.7% (2 4/6 2) were significantly lower than those in laryngeal cancer tissues [85.2% (6/91/81), 61.1% (56/81) and 62.9% (51 / 81), P <0 .01]. (4) CD4 4 v6, v9 and P5 3 in cervical lymph node metastasis?